ArticleScientific reports2025
Reducing inference cost of Alzheimer's disease identification using an uncertainty-aware ensemble of uni-modal and multi-modal learners.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal deep learning for inflammatory bowel disease: a new frontier in cellular and molecular biomarker discovery to clinical translation.Journal of biological engineering · 2026Review
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Recent Advancements in Neuroimaging-Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review.Health science reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
While multi-modal deep learning approaches trained using magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG PET) data have shown promise in the accurate identification of Alzheimer's disease, their clinical applicability is hindered by the assumption that both modalities are always available during model inference. In practice, clinicians adjust diagnostic tests based on available information and specific clinical contexts. We propose a novel MRI- and FDG PET-based multi-modal deep learning approach that mimics clinical decision-making by incorporating uncertainty estimates of an MRI-based model (generated using Monte Carlo dropout and evidential deep learning) to determine the necessity of an FDG PET scan, and only inputting the FDG PET to a multi-modal model when required. This approach significantly reduces the reliance on FDG PET scans, which are costly and expose patients to radiation. Our approach reduces the need for FDG PET by up to 92% without compromising model performance, thus optimizing resource use and patient safety. Furthermore, using a global model explanation technique, we provide insights into how anatomical changes in brain regions-such as the entorhinal cortex, amygdala, and ventricles-can positively or negatively influence the need for FDG PET scans in alignment with clinical understanding of Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.